This Threat Assessment Brief considers the risk of infection related to avian influenza A(H5N8) virus to the general population and the occupationally exposed.
The influenza vaccination communication guide provide advice, guidance and campaign materials to support national influenza vaccination campaigns with the purpose of increasing the influenza vaccination uptake in the EU Member States.
Based on a systematic literature review, ECDC assessed the efficacy, effectiveness and safety of newer and enhanced inactivated seasonal influenza (flu) vaccines among those 18 years or older. These assessed are MF59® adjuvanted, cell-based, high-dose, and recombinant haemagglutinin influenza vaccines.
The Flu Awareness Week is marked across the WHO European Region every year in October. It aims to raise awareness of the importance of vaccination for people’s health and well-being and to increase the uptake of seasonal influenza vaccination of people with underlying risk factors.
Organized by:World Health Organization (WHO) - Regional office for Europe
Overall the evidence base for the efficacy and effectiveness of newer and enhanced influenza vaccines appears limited at present, with a number of potentially relevant studies identified as ongoing.
A recently published study conducted between 2011 and 2018 in China, and based on surveillance data in pigs, identified an emerging genotype 4 (G4) reassortant Eurasian avian-like (EA) A(H1N1) swine influenza virus that contains internal genes from the human A(H1N1)pdm09 and North American triple-reassortant (TR) lineage-derived internal genes.
This issue of the CDTR (Communicable Disease Threats Report) covers the period from 1-7 March 2020 and includes updates on COVID-19, Ebola virus disease, polio, influenza, MERS-CoV.